Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Full IRB Study Title:
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
IRB Study ID: 1118157-1
For complete study information, please view the study on clinicaltrials.gov
This study is being done in collaboration with Cincinnati Children's Hospital.
Study Sponsor:
Children’s Oncology Group
